References
- Magistris MTD, Alexander J, Coggeshall M, Altman A, Gaeta FCA, Grey HM, et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992; 68:625–34.
- Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentia-tion in vivo. J Exp Med 1995;181:1569–74.
- Chen YZ, Matsushita S, Nishimura Y. Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide. J Immunol 1996;157: 3783–90.
- Ohnishi Y, Tsutsumi A, Sakamaki T, Sumida T. T cell epitopes of type II collagen in HLA-DRB1*0101 or DRB1*0405-positive Japa-nese patients with rheumatoid arthritis. Int J Mol Med 2003;11:331–
- Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: 315–24.
- Rosloniec EF, Whittington KB, Zaller DM, Kang AH. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 2002;168:253–9.
- Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type 11 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell response. Human Immunol 2000;61: 640–50.
- Myers LK, Sakurai Y, Tang B, He X, Rosloniec EF, Stuart JM, et al. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum 2002;46:3369–77.